In-vitro selection of porin-deficient mutants of two strains of Klebsiella pneumoniae with reduced susceptibilities to meropenem, but not to imipenem
- PMID: 10052909
- DOI: 10.1093/jac/42.6.821
In-vitro selection of porin-deficient mutants of two strains of Klebsiella pneumoniae with reduced susceptibilities to meropenem, but not to imipenem
Abstract
We have evaluated the ability of imipenem and meropenem to select, in vitro, resistant mutants of two clinical isolates of Klebsiella pneumoniae producing both SHV and TEM beta-lactamases. Only meropenem selected mutants of both isolates for which the MICs of meropenem, but not imipenem, were markedly higher than those for the parent strains; the MICs of several other beta-lactam antibiotics, including beta-lactam/beta-lactamase inhibitor combinations, for these mutants were also higher than those for the parent strains. In contrast, the MICs for the imipenem-selected mutants were the same as, or similar to, those for the parent strains. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis analysis revealed that an outer membrane protein in both parent strains was absent in the meropenem-selected mutants, but not in the imipenem-selected mutants. This protein is likely to be a porin, the absence of which is presumably associated with impaired beta-lactam permeability and, therefore, the reduced susceptibilities to these antibiotics exhibited by the mutant strains. We believe that this is the first report of the in-vitro selection of porin-deficient mutants of K. pneumoniae following exposure to meropenem.
Similar articles
-
Prevalence and mechanisms of decreased susceptibility to carbapenems in Klebsiella pneumoniae isolates.Diagn Microbiol Infect Dis. 2007 Jan;57(1):85-91. doi: 10.1016/j.diagmicrobio.2006.05.008. Epub 2006 Jul 18. Diagn Microbiol Infect Dis. 2007. PMID: 16854555
-
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01694-17. doi: 10.1128/AAC.01694-17. Print 2017 Dec. Antimicrob Agents Chemother. 2017. PMID: 29038260 Free PMC article.
-
Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.Clin Microbiol Infect. 2005 Jan;11(1):31-8. doi: 10.1111/j.1469-0691.2004.01018.x. Clin Microbiol Infect. 2005. PMID: 15649301
-
Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.Diagn Microbiol Infect Dis. 2011 Sep;71(1):87-9. doi: 10.1016/j.diagmicrobio.2010.12.012. Epub 2011 Mar 11. Diagn Microbiol Infect Dis. 2011. PMID: 21397426
-
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Drugs. 2018. PMID: 29230684 Review.
Cited by
-
Meropenem: an updated review of its use in the management of intra-abdominal infections.Drugs. 2000 Sep;60(3):619-46. doi: 10.2165/00003495-200060030-00010. Drugs. 2000. PMID: 11030471 Review.
-
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.Antimicrob Agents Chemother. 2001 Apr;45(4):1151-61. doi: 10.1128/AAC.45.4.1151-1161.2001. Antimicrob Agents Chemother. 2001. PMID: 11257029 Free PMC article.
-
Meropenem: a review of its use in patients in intensive care.Drugs. 2000 Mar;59(3):653-80. doi: 10.2165/00003495-200059030-00016. Drugs. 2000. PMID: 10776838 Review.
-
High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe.Antimicrob Agents Chemother. 2006 Oct;50(10):3396-406. doi: 10.1128/AAC.00285-06. Antimicrob Agents Chemother. 2006. PMID: 17005822 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources